Search by Drug Name or NDC
NDC 59651-0379-60 Zonisamide 50 mg/1 Details
Zonisamide 50 mg/1
Zonisamide is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Aurobindo Pharma Limited. The primary component is ZONISAMIDE.
MedlinePlus Drug Summary
Zonisamide is used in combination with other medications to treat certain types of seizures. Zonisamide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
Related Packages: 59651-0379-60Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Zonisamide
Product Information
| NDC | 59651-0379 |
|---|---|
| Product ID | 59651-379_dcf4edca-de05-4f9b-b78c-feda19a49891 |
| Associated GPIs | 72600090000110 |
| GCN Sequence Number | 053368 |
| GCN Sequence Number Description | zonisamide CAPSULE 50 MG ORAL |
| HIC3 | H4B |
| HIC3 Description | ANTICONVULSANTS |
| GCN | 20833 |
| HICL Sequence Number | 021140 |
| HICL Sequence Number Description | ZONISAMIDE |
| Brand/Generic | Generic |
| Proprietary Name | Zonisamide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Zonisamide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/1 |
| Substance Name | ZONISAMIDE |
| Labeler Name | Aurobindo Pharma Limited |
| Pharmaceutical Class | Anti-epileptic Agent [EPC], Carbonic Anhydrase Inhibitors [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], P-Glycoprotein Inhibitors [MoA], Sulfonamides [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA077645 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 59651-0379-60 (59651037960)
| NDC Package Code | 59651-379-60 |
|---|---|
| Billing NDC | 59651037960 |
| Package | 60 CAPSULE in 1 BOTTLE (59651-379-60) |
| Marketing Start Date | 2020-08-17 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |